seemingly harmless, these are excellent questions which deserve answers and not approximations.
**On whether HLA class I loss can be measured and quantified, and how frequently it occurs:**
Yes, it is directly measurable. HLA class I surface expression is assessed by immunohistochemistry using antibodies like W6/32, which detects the conformationally intact HLA class I heavy chain/Beta-2 Microglobulin complex on the tumor cell surface. Loss of surface expression is visible on a stained biopsy slide. Beta-2 Microglobulin mutations and HLA loss of heterozygosity are additionally detectable through tumor whole exome sequencing and RNA sequencing, and are now routinely assessed in comprehensive genomic profiling panels at major cancer centers.
The frequency data is tumor-type dependent and clinically significant. Somatic HLA class I loss of heterozygosity occurs in more than 20 percent of squamous cell carcinomas including esophageal and head and neck cancers, and loss of heterozygosity of chromosome 6 was observed in approximately 40 percent of non-small cell lung cancer cases. Even if HLA class I expression is sustained, mutations or deletions affecting Beta-2 Microglobulin lead to loss of HLA class I from the cell surface, preventing stable expression and resulting in loss of function. A significant prevalence of HLA-A and B2M loss of up to 65 percent has been confirmed depending on indication, with heterogeneous expression patterns across patients and indications. The critical framing is this: HLA class I loss is not uniformly present at diagnosis. A gradient of expression exists between normal cells, primary tumors, and metastatic tumors, meaning the loss accumulates under immune pressure over time and across treatment lines. This maps directly onto your treatment slot framework.
https://www.prnewswire.com/news-releases/skyr...70300.html
https://www.gastrojournal.org/article/S0016-5...2/fulltext
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974621/
**On whether PD-1/PD-L1 develops first and then mutates toward TIM-3, LAG-3, or TIGIT, or whether they co-develop simultaneously:**
The published literature is clear on this and the answer matters clinically. They are not strictly sequential, but they are not equal either. Exhausted T cells display sustained upregulation of inhibitory receptors including PD-1, CTLA-4, LAG-3, TIM-3, 2B4, CD39, CD160, BTLA and TIGIT, in a progressive and hierarchical loss of effector functions. The hierarchy is real: PD-1 upregulation is the earliest and most dominant exhaustion signal. The effect of PD-1 blockade is proportionally larger than that of LAG-3, TIM-3, or TIGIT blockade alone, which reflects PD-1's position as the primary brake in the exhaustion cascade. However, the alternative checkpoints are not simply waiting their turn. In peripheral CD8+ T cells from cervical cancer patients, significant upregulation of exhaustion-associated markers PD-1, TIGIT, TIM-3, and LAG-3 were found simultaneously, with these same molecules further upregulated in tumor-infiltrating lymphocytes. The practical implication is that co-expression is the clinical reality, not strict sequencing. And critically, TIM-3 upregulation can be observed after anti-PD-1 therapy, confirming that ICI treatment itself accelerates the pivot to alternative checkpoints exactly as your intuition suggested.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11850322/
https://pmc.ncbi.nlm.nih.gov/articles/PMC5770570/
https://academic.oup.com/intimm/article/17/8/1023/683473
https://pmc.ncbi.nlm.nih.gov/articles/PMC10545720/
**On your treatment slot framework and where HLA class I loss fits:**
Your mapping is accurate with a refinement worth adding. HLA class I loss is not equally likely across all slots. It is most likely to emerge or intensify at two specific points: under spontaneous immune pressure in slots 2 and 3, as the immune system exerts selection pressure on the tumor population and cancer cells with intact HLA class I are preferentially eliminated, leaving HLA-loss variants to dominate; and under ICI therapy pressure in slots 4 and 5, where the reinvigorated CD8+ T cell response creates even stronger selection pressure for HLA-negative escape variants. The cells that lose HLA class I expression survive the CD8+ attack. Their progeny become the dominant clone. This is measurable longitudinally by tracking HLA expression on circulating tumor cells between treatment lines.
**On the cancer PrEP framing and early-stage CCR5 blockade:**
This is the most creative question in your comment and it has genuine preclinical support, even if the clinical trial infrastructure to test it doesn't exist yet. Leronlimab reduced lung metastasis of the TNBC cell line MDA-MB-231 by more than 98 percent at six weeks in xenograft models, and also reduced the metastatic tumor burden of established TNBC lung metastasis. The anti-metastatic mechanism operates through the CCL5/CCR5 axis on tumor cells themselves, the same axis the CCR5 receptor uses to direct tumor cell extravasation and seeding at distant sites. This is distinct from the immune trafficking argument and adds a second layer to your cancer PrEP hypothesis: CCR5 blockade in early-stage disease would not only preserve immune surveillance by preventing myeloid suppressive cell recruitment, it would also directly impair the tumor cell's metastatic machinery before it has the opportunity to seed distant sites.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12694645/
CCR5 is overexpressed in approximately 95 percent of triple-negative breast cancer and is associated with resistance to PD-1/PD-L1 checkpoint inhibitors. In a population where CCR5 expression is that prevalent, early blockade before metastatic seeding occurs is a coherent chemoprevention hypothesis. The obstacle is not biological plausibility but regulatory and commercial pathway: cancer prevention trials require enormous populations, long follow-up windows, and a risk-benefit calculation heavily weighted toward safety given the healthy or early-stage patient population. Leronlimab's safety profile, with zero grade three or four adverse events across the entire enrolled CLOVER population, is precisely the kind of clean safety record a chemoprevention hypothesis requires. Whether anyone ever designs and funds that trial is a different question.
https://pubmed.ncbi.nlm.nih.gov/40885373/
Your slot framework is sound. The biology fills in the gaps you identified exactly as you suspected it would.
**On whether HLA class I loss can be measured and quantified, and how frequently it occurs:**
Yes, it is directly measurable. HLA class I surface expression is assessed by immunohistochemistry using antibodies like W6/32, which detects the conformationally intact HLA class I heavy chain/Beta-2 Microglobulin complex on the tumor cell surface. Loss of surface expression is visible on a stained biopsy slide. Beta-2 Microglobulin mutations and HLA loss of heterozygosity are additionally detectable through tumor whole exome sequencing and RNA sequencing, and are now routinely assessed in comprehensive genomic profiling panels at major cancer centers.
The frequency data is tumor-type dependent and clinically significant. Somatic HLA class I loss of heterozygosity occurs in more than 20 percent of squamous cell carcinomas including esophageal and head and neck cancers, and loss of heterozygosity of chromosome 6 was observed in approximately 40 percent of non-small cell lung cancer cases. Even if HLA class I expression is sustained, mutations or deletions affecting Beta-2 Microglobulin lead to loss of HLA class I from the cell surface, preventing stable expression and resulting in loss of function. A significant prevalence of HLA-A and B2M loss of up to 65 percent has been confirmed depending on indication, with heterogeneous expression patterns across patients and indications. The critical framing is this: HLA class I loss is not uniformly present at diagnosis. A gradient of expression exists between normal cells, primary tumors, and metastatic tumors, meaning the loss accumulates under immune pressure over time and across treatment lines. This maps directly onto your treatment slot framework.
https://www.prnewswire.com/news-releases/skyr...70300.html
https://www.gastrojournal.org/article/S0016-5...2/fulltext
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974621/
**On whether PD-1/PD-L1 develops first and then mutates toward TIM-3, LAG-3, or TIGIT, or whether they co-develop simultaneously:**
The published literature is clear on this and the answer matters clinically. They are not strictly sequential, but they are not equal either. Exhausted T cells display sustained upregulation of inhibitory receptors including PD-1, CTLA-4, LAG-3, TIM-3, 2B4, CD39, CD160, BTLA and TIGIT, in a progressive and hierarchical loss of effector functions. The hierarchy is real: PD-1 upregulation is the earliest and most dominant exhaustion signal. The effect of PD-1 blockade is proportionally larger than that of LAG-3, TIM-3, or TIGIT blockade alone, which reflects PD-1's position as the primary brake in the exhaustion cascade. However, the alternative checkpoints are not simply waiting their turn. In peripheral CD8+ T cells from cervical cancer patients, significant upregulation of exhaustion-associated markers PD-1, TIGIT, TIM-3, and LAG-3 were found simultaneously, with these same molecules further upregulated in tumor-infiltrating lymphocytes. The practical implication is that co-expression is the clinical reality, not strict sequencing. And critically, TIM-3 upregulation can be observed after anti-PD-1 therapy, confirming that ICI treatment itself accelerates the pivot to alternative checkpoints exactly as your intuition suggested.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11850322/
https://pmc.ncbi.nlm.nih.gov/articles/PMC5770570/
https://academic.oup.com/intimm/article/17/8/1023/683473
https://pmc.ncbi.nlm.nih.gov/articles/PMC10545720/
**On your treatment slot framework and where HLA class I loss fits:**
Your mapping is accurate with a refinement worth adding. HLA class I loss is not equally likely across all slots. It is most likely to emerge or intensify at two specific points: under spontaneous immune pressure in slots 2 and 3, as the immune system exerts selection pressure on the tumor population and cancer cells with intact HLA class I are preferentially eliminated, leaving HLA-loss variants to dominate; and under ICI therapy pressure in slots 4 and 5, where the reinvigorated CD8+ T cell response creates even stronger selection pressure for HLA-negative escape variants. The cells that lose HLA class I expression survive the CD8+ attack. Their progeny become the dominant clone. This is measurable longitudinally by tracking HLA expression on circulating tumor cells between treatment lines.
**On the cancer PrEP framing and early-stage CCR5 blockade:**
This is the most creative question in your comment and it has genuine preclinical support, even if the clinical trial infrastructure to test it doesn't exist yet. Leronlimab reduced lung metastasis of the TNBC cell line MDA-MB-231 by more than 98 percent at six weeks in xenograft models, and also reduced the metastatic tumor burden of established TNBC lung metastasis. The anti-metastatic mechanism operates through the CCL5/CCR5 axis on tumor cells themselves, the same axis the CCR5 receptor uses to direct tumor cell extravasation and seeding at distant sites. This is distinct from the immune trafficking argument and adds a second layer to your cancer PrEP hypothesis: CCR5 blockade in early-stage disease would not only preserve immune surveillance by preventing myeloid suppressive cell recruitment, it would also directly impair the tumor cell's metastatic machinery before it has the opportunity to seed distant sites.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12694645/
CCR5 is overexpressed in approximately 95 percent of triple-negative breast cancer and is associated with resistance to PD-1/PD-L1 checkpoint inhibitors. In a population where CCR5 expression is that prevalent, early blockade before metastatic seeding occurs is a coherent chemoprevention hypothesis. The obstacle is not biological plausibility but regulatory and commercial pathway: cancer prevention trials require enormous populations, long follow-up windows, and a risk-benefit calculation heavily weighted toward safety given the healthy or early-stage patient population. Leronlimab's safety profile, with zero grade three or four adverse events across the entire enrolled CLOVER population, is precisely the kind of clean safety record a chemoprevention hypothesis requires. Whether anyone ever designs and funds that trial is a different question.
https://pubmed.ncbi.nlm.nih.gov/40885373/
Your slot framework is sound. The biology fills in the gaps you identified exactly as you suspected it would.
12
